What are clinical trails?
Clinical trials are investigative studies that examine the safety and efficacy of medical devices, treatments, or strategies specifically for human use. If this may seem intimidating, it is essential to note that our trials are renowned for prioritizing patient safety, upholding participants’ rights, relying on robust scientific evidence, undergoing scrutiny from independent committees, and adhering to relevant laws and regulations governing research.
Why participate in a clinical trial?
Care at no cost: Our clinical trials offer qualifying participants care services at no charge, ensuring they can receive treatment even if it is financially challenging to access it elsewhere.
Latest Treatments: Qualifying participants gain access to groundbreaking treatments and potentially life-changing medications currently available or unavailable elsewhere; the best part is that they are provided free of charge.
Possible Financial Benefits: Qualifying participants receive free treatments within our trials. Additionally, in most instances, we offer compensation for participants’ time, travel, and participation.
Help Others: Numerous individuals choose to participate in clinical trials because it gives them a chance to make a difference in the lives of others.
Gain knowledge: By participating in trials, you can enhance your understanding of your health, empowering yourself to take control and develop a deeper awareness of your condition. In doing so, you may even cultivate a more optimistic outlook on your well-being.
Leading Specialists: The researchers leading our clinical trials are experts in their field. Their knowledge and experience are why they were chosen to conduct the trial.
Legal Notice: The benefits described above are subject to change and may vary depending on the specific clinical trial. These benefits are applicable exclusively to participants who qualify following the completion of the screening process.
Current Clinical Trails
STABILIZE-CKD
Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with CKD and Hyperkalemia or at Risk of Hyperkalemia
Status: Enrolling
Type of Study: A Phase 3, International, Randomized, Double-Blind,
Placebo Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Patients with CKD and Hyperkalemia or at Risk of Hyperkalemia
Study Length: 28 months
Target Age/Sex: Over 18 years, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://clinicaltrials.gov/ct2/show/NCT05056727
Description:
This is a Phase 3, international, randomized withdrawal, double-blind, parallel-group, placebo-controlled study, to evaluate the effect of SZC as adjunct to RAASi therapy (lisinopril or valsartan) in slowing CKD progression in participants with CKD and hyperkalemia or at risk of hyperkalemia.
Specifically, the study will include participants with hyperkalemia (S-K > 5.0 to ≤ 6.5 mmol/L by central laboratory) who are on adequate or limited RAASi therapy due to hyperkalemia, and participants with normokalaemia (S-K ≥ 3.5 to ≤ 5.0 mmol/L by central laboratory) who are on limited RAASi therapy due to high risk of hyperkalemia. High risk of hyperkalemia is defined as (1) participants with a previous medical history or record of hyperkalemia within the prior 24 months who are on limited RAASi therapy despite indication in CKD; (2) participants in whom RAASi therapy is indicated in CKD but are on limited RAASi therapy and have S-K ≥ 4.7 to ≤ 5.0 mmol/L; and (3) participants in whom RAASi therapy has been discontinued or reduced to suboptimal doses because of hyperkalemia.
Status: Enrolling
Type of Study: A Phase 3, Open-Label Study of Once Daily LY3502970
Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes
and Obesity or Overweight at Increased Cardiovascular Risk.
Study Length: 104 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://classic.clinicaltrials.gov/ct2/show/NCT05803421
Description:
ACHIEVE-4 is a clinical research study to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
QWINT-3
The QWINT-3 Study is testing an investigational basal insulin taken once weekly compared with basal insulin that is taken daily.
Status: Enrollment Completed
Type of Study: A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Study Length: 86 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://classic.clinicaltrials.gov/ct2/show/NCT03736785
Description:
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes that have already been treated with basal insulin.
ACHIEVE-1
Effect of LY3502970 Compared with Placebo in Participants with Type 2 Diabetes Inadequately Controlled with Diet and Exercise Alone
Status: Enrolling
Type of Study: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 compared with Placebo in Adult Participants with Type 2 Diabetes and inadequate Glycemic Control with Diet and Exercise Alone.
Study Length: 42 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://classic.clinicaltrials.gov/ct2/show/NCT03736785
Description:
The reason for this study is to compare the effects of LY3502970 and placebo on body weight and overall safety profile.
Upcoming
SYNCHRONIZE™-1
Efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes.
Status: Upcoming
Type of Study: A Phase III, randomized, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes.
Study Length: 76 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Description:
This trial aims to provide evidence of the efficacy, safety, and tolerability of BI 456906 4.8 mg and 6.0 mg once weekly as an adjunct to a reduced-calorie diet and increased physical activity in comparison to placebo to BI 456906 in participants with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight-related co-morbidities but without T2DM.
SYNCHRONIZE™-2
A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight.
Status: Upcoming
Type of Study: A Phase 3, randomized, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus.
Study Length: 76 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Description:
The trial will compare BI 456906 3.6 mg with placebo, and BI 456906 6.0 mg with placebo as an adjunct to a reduced-calorie
diet and increased physical activity in trial participants with a BMI ≥27 kg/m2 and T2DM in terms of efficacy and safety.
Over 40 Previous Studies
SURMOUNT-2
Efficacy and Safety of Tirzepatide Once Weekly versus Placebo in Participants with Type 2 Diabetes Who Have Obesity or Are Overweight with Weight-Related Comorbidities
CSL346_2001
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease.
ANJ900D3501